Early Detection of Prostate Cancer by FACS

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Ziv Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Ziv Hospital
ClinicalTrials.gov Identifier:
NCT00524823
First received: September 3, 2007
Last updated: September 4, 2007
Last verified: August 2007
  Purpose

Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.


Condition Phase
Prostate Cancer
Hyperplasia
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by Ziv Hospital:

Estimated Enrollment: 40
Study Start Date: August 2007
Groups/Cohorts
Case: 1
10 diagnosed men in age 60 - 90 with Prostate Cancer
Case: 2
10 patients with benign growth
Control: 3
10 health volunteers
Control: 4
10 patients diagnosed with other cancer

  Eligibility

Ages Eligible for Study:   60 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Experimental group : Males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment.

Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -BPH.

Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy.

Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate.

Exclusion Criteria:

Experimental group: Other known cancer or systemic infection. Control Group 1: Other known cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. Patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections.

Control Group 3:Other known systemic infection, nor urinary tract infection.

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00524823

Contacts
Contact: Nina Kucherski, MD 050-8434041
Contact: Yihia Johari, MD 050-8434094

Locations
Israel
Urology Department, Ziv Medical Center Recruiting
Safed, Israel, 20100
Contact: Yihia Johari, MD         
Sub-Investigator: Yihia Johari, MD         
Sponsors and Collaborators
Ziv Hospital
Investigators
Principal Investigator: Nina Kucherski, MD Ziv Medical Center
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00524823     History of Changes
Other Study ID Numbers: HP 7-251 S
Study First Received: September 3, 2007
Last Updated: September 4, 2007
Health Authority: Israel: The Israel National Institute for Health Policy Research and Health Services Research

Keywords provided by Ziv Hospital:
Prostate Cancer
Hyperplasia - BPH
FACS
Prostate Cancer, Hyperplasia - BPH, Malignancy

Additional relevant MeSH terms:
Hyperplasia
Prostatic Neoplasms
Pathologic Processes
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on August 21, 2014